Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial

Seo et al., Infection & Chemotherapy, doi:10.3947/ic.2021.0142
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Progression 0% Improvement Relative Risk Progression, PP 34% Time to progression 13% Fluvoxamine  Seo et al.  EARLY TREATMENT  RCT Is early treatment with fluvoxamine beneficial for COVID-19? RCT 52 patients in South Korea (January - February 2021) Trial underpowered to detect differences c19early.org Seo et al., Infection & Chemotherapy, Mar 2022 Favors fluvoxamine Favors control
26th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Early terminated RCT with 52 COVID+ patients in South Korea, showing no significant difference in progression with fluvoxamine treatment. There were only 2 events in each arm, and only one event for fluvoxamine in PP analysis. The trial was terminated early because the treatment center closed. 100mg fluvoxamine bid for 10 days.
risk of progression, no change, RR 1.00, p = 1.00, treatment 2 of 26 (7.7%), control 2 of 26 (7.7%).
risk of progression, 34.2% lower, RR 0.66, p = 1.00, treatment 1 of 19 (5.3%), control 2 of 25 (8.0%), NNT 37, PP.
time to progression, 13.3% lower, relative time 0.87, p = 0.16, treatment mean 6.5 (±0.7) n=26, control mean 7.5 (±3.5) n=26.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Seo et al., 3 Mar 2022, Single Blind Randomized Controlled Trial, placebo-controlled, South Korea, peer-reviewed, median age 53.5, 14 authors, study period 15 January, 2021 - 19 February, 2021.
This PaperFluvoxamineAll
Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
Hyeonji Seo, Haein Kim, Seongman Bae, Seonghee Park, Hyemin Chung, Heung-Sup Sung, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Ki Young Son, MD Yong Pil Chong
Infection & Chemotherapy, doi:10.3947/ic.2021.0142
Background: This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and Methods: A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real timepolymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results: Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 -60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group (P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion: In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo.
SUPPLEMENTARY MATERIALS Supplementary document 1 Supplementary Table 1 Primary and secondary outcomes in the per-protocol analysis Click here to view Supplementary Table 2 Baseline and clinical characteristics of patients admitted to CTC according to the outcome Click here to view Supplementary Table 3 Results of analyses of risk factors for transfer to hospital due to clinical deterioration Click here to view
References
Ahmad, Cisewski, Miniño, Anderson, Provisional mortality data -United States, 2020, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7014e1
Almási, Török, Valkusz, Tajti, Csonka et al., Sigma-1 receptor engages an anti-inflammatory and antioxidant feedback loop mediated by peroxiredoxin in experimental colitis, Antioxidants, doi:10.3390/antiox9111081
Beigel, Tomashek, Dodd, Mehta, Zingman et al., ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -Final Report, N Engl J Med, doi:10.1056/NEJMoa2007764
Feng, Yu, Yao, Luo, Zhou et al., Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics, Nat Commun, doi:10.1038/s41467-020-18786-x
Gandhi, Lynch, Rio, Mild or moderate Covid-19, N Engl J Med, doi:10.1056/NEJMcp2009249
Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci, doi:10.1007/s00406-020-01231-x
Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry, doi:10.1038/s41380-021-01021-4
Kang, Lee, Jung, Kim, Cho et al., Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea, Emerg Infect Dis, doi:10.3201/eid2610.201460
Kim, Kim, Lee, Lee, Discovering spatiotemporal patterns of COVID-19 pandemic in South Korea, Sci Rep, doi:10.1038/s41598-021-03487-2
Kim, Yoo, Heo, Lee, Oh, Clinical characteristics and risk factors for severe disease of coronavirus disease 2019 in a low case fatality rate region in Korea, Infect Chemother, doi:10.3947/ic.2021.0104
Lee, Hong, Kim, Lee, Lee, Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea, Emerg Infect Dis
Lee, Song, Lim, Kim, Chai et al., Operation and management of Seoul metropolitan city community treatment center for mild condition COVID-19 patients, J Korean Med Sci, doi:10.3346/jkms.2020.35.e367
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial, JAMA, doi:10.1001/jama.2020.22760
Medical, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, doi:10.1001/jama.2013.281053
Park, Kim, Heo, Kim, Park et al., Out-of-hospital cohort treatment of coronavirus disease 2019 patients with mild symptoms in Korea: an experience from a single community treatment center, J Korean Med Sci, doi:10.3346/jkms.2020.35.e140
Park, Lee, Lim, Lim, Hong et al., Presenting characteristics and clinical outcome of patients with COVID-19 in South Korea: A nationwide retrospective observational study, Lancet Reg Health West Pac, doi:10.1016/j.lanwpc.2020.100061
Peck, Collaborative response to COVID-19 pandemic, and development of treatment guidelines, Infect Chemother
Pubmed | Crossref, None, doi:10.3201/eid2610.201620
Pubmed | Crossref, None, doi:10.3947/ic.2021.0301
Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/S2214-109X(21)00448-4
Salama, Han, Yau, Reiss, Kramer et al., Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia, N Engl J Med, doi:10.1056/NEJMoa2030340
Seftel, Boulware, Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19, Open Forum Infect Dis, doi:10.1093/ofid/ofab050
Undurraga, Chowell, Mizumoto, COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March-August 2020, Infect Dis Poverty, doi:10.1186/s40249-020-00785-1
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Zarandi, Zinatizadeh, Zinatizadeh, Yousefi, Rezaei, SARS-CoV-2: From the pathogenesis to potential anti-viral treatments, Biomed Pharmacother, doi:10.1016/j.biopha.2021.111352
{ 'indexed': {'date-parts': [[2022, 3, 10]], 'date-time': '2022-03-10T08:15:41Z', 'timestamp': 1646900141005}, 'reference-count': 0, 'publisher': 'Korean Society of Infectious Diseases and Korean Society for Chemotherapy', 'license': [ { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Infect Chemother'], 'DOI': '10.3947/ic.2021.0142', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 10]], 'date-time': '2022-03-10T07:51:52Z', 'timestamp': 1646898712000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A ' 'Preliminary Result of Randomized Controlled Trial'], 'prefix': '10.3947', 'volume': '54', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6659-6853', 'authenticated-orcid': False, 'given': 'Hyeonji', 'family': 'Seo', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}, { 'name': 'Division of Infectious Diseases, Department of Internal ' 'Medicine, Hallym University Sacred Heart Hospital, Hallym ' 'University College of Medicine, Anyang, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0003-2002-1098', 'authenticated-orcid': False, 'given': 'Haein', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0001-6375-3657', 'authenticated-orcid': False, 'given': 'Seongman', 'family': 'Bae', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0003-2902-8341', 'authenticated-orcid': False, 'given': 'Seonghee', 'family': 'Park', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-4447-975X', 'authenticated-orcid': False, 'given': 'Hyemin', 'family': 'Chung', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6062-4451', 'authenticated-orcid': False, 'given': 'Heung-sup', 'family': 'Sung', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Laboratory Medicine, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0003-4333-3270', 'authenticated-orcid': False, 'given': 'Jiwon', 'family': 'Jung', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-5489-8608', 'authenticated-orcid': False, 'given': 'Min Jae', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6596-8253', 'authenticated-orcid': False, 'given': 'Sung-Han', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0003-1381-8787', 'authenticated-orcid': False, 'given': 'Sang-Oh', 'family': 'Lee', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-4972-4531', 'authenticated-orcid': False, 'given': 'Sang-Ho', 'family': 'Choi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6785-8824', 'authenticated-orcid': False, 'given': 'Yang Soo', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-5592-7458', 'authenticated-orcid': False, 'given': 'Ki Young', 'family': 'Son', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Family Medicine, Asan Medical Center, University ' 'of Ulsan College of Medicine, Seoul, Korea.'}]}, { 'ORCID': 'http://orcid.org/0000-0003-1672-3185', 'authenticated-orcid': False, 'given': 'Yong Pil', 'family': 'Chong', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Diseases, Asan Medical Center, ' 'University of Ulsan College of Medicine, Seoul, Korea.'}]}], 'member': '2343', 'published-online': {'date-parts': [[2022]]}, 'container-title': ['Infection & Chemotherapy'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://icjournal.org/pdf/10.3947/ic.2021.0142', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://icjournal.org/DOIx.php?id=10.3947/ic.2021.0142', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://icjournal.org/DOIx.php?id=10.3947/ic.2021.0142', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 10]], 'date-time': '2022-03-10T07:51:52Z', 'timestamp': 1646898712000}, 'score': 1, 'resource': {'primary': {'URL': 'https://icjournal.org/DOIx.php?id=10.3947/ic.2021.0142'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.3947/ic.2021.0142', 'relation': {}, 'ISSN': ['2093-2340', '2092-6448'], 'issn-type': [{'value': '2093-2340', 'type': 'print'}, {'value': '2092-6448', 'type': 'electronic'}], 'subject': ['Pharmacology (medical)', 'Infectious Diseases'], 'published': {'date-parts': [[2022]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit